Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOPAPS: Switching to Omidenepag Isopropyl in Glaucoma with PAP
NCT05279716Phase 4Unknown
- Sponsor
- Santen Pharmaceutical
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omidenepag isopropyl in normal tension glaucoma (NTG), primary open-angle glaucoma (POAG), ocular hypertension, glaucoma suspect, sponsored by Santen Pharmaceutical. Status: unknown.
02
Drugs
omidenepag isopropyl
03
Conditions
normal tension glaucoma (NTG)primary open-angle glaucoma (POAG)ocular hypertensionglaucoma suspect
Beyond the preview
Go deeper on NCT05279716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279716.